//
SAN FRANCISCO, October 3, 2023 — The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will…
As we start 2022, thank you for inspiring all of us at the SRF to remain laser-focused on our mission—finding a cure for scleroderma. And thanks to the support of our…